Status:
COMPLETED
Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma
Lead Sponsor:
Galderma R&D
Conditions:
Melasma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To determine the effectiveness and safety of sequential therapy with of Tri-Luma® Cream and a series of Glycolic Acid peels in treatment of moderate to severe melasma.
Detailed Description
To determine the efficacy and safety of sequential therapy with Fluocinolone acetonide 0.01%, Hydroquinone 4% and Tretinoin 0.05%, and a series of Glycolic Acid peels in the treatment of moderate to s...
Eligibility Criteria
Inclusion
- Subjects diagnosed with moderate to severe melasma
Exclusion
- Subjects under treatment for a dermatologic condition, which may interfere with the safe evaluation of the study combination (e.g. eczema, psoriasis, severe sun-damage, dermatitis)
- Subjects with a diagnosis of skin cancer (BCE, SCC, Melanoma) in the areas to be treated
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00472966
Start Date
November 1 2006
End Date
April 1 2007
Last Update
July 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Skin Care Research, Inc.
Boca Raton, Florida, United States, 33486